[Skip to Content]
[Skip to Content Landing]
Article
March 1990

Tumor ImmunizationImproved Results After Vaccine Modified With Recombinant Interferon Gamma

Author Affiliations

From the Harrison Department of Surgical Research, the University of Pennsylvania School of Medicine, Philadelphia (Drs Sigal, Lieberman, Reynolds, Williams, and Daly) and the Joseph Stokes Jr Research Institute, the Childrens Hospital of Philadelphia (Dr Ziegler). Dr Reynolds is now with the Hull (England) Royal Infirmary.

Arch Surg. 1990;125(3):308-312. doi:10.1001/archsurg.1990.01410150030006
Abstract

•The purpose of this study was to determine if a 3-day in vitro culture of the murine neuroblastoma C1300 with 500 U/mL of recombinant interferon gamma resulted in a protective crossreactivity to parent C1300. Twenty A/J mice received either a vaccine of 1 × 106 irradiated C1300 tumor cells intradermally or an equivalent innoculum of C1300 that had been incubated in recombinant interferon gamma (C1300*). One week later, all animals were rechallenged with 1 × 106 viable C1300. Animals immunized with C1300* had a significantly delayed early tumor incidence that translated into a survival advantage for the group. At the time of tumor rechallenge, a significantly increased level of nonspecific systemic immunity was conferred by the C1300* immunization. Thus, modification of tumor with recombinant interferon gamma before introduction as a vaccine may improve that vaccine's protective capability.

(Arch Surg. 1990;125:308-312)

×